The FDA has approved Journavx (suzetrigine), a new non-addictive medication for acute pain management, providing a significant alternative to traditional opioid-based painkillers. This breakthrough addresses concerns surrounding addiction while offering patients a viable treatment option. The drug works by blocking pain signals before they reach the brain, presenting a refined approach compared to earlier pain medications. Experts highlight that this approval represents a critical public health milestone that could transform pain treatment and potentially pave the way for further development of similar therapies in the future.
The FDA approved Journavx (suzetrigine), a non-addictive painkiller for acute pain, marking an important public health milestone in managing pain without addiction risks.
Dr. Jacqueline Corrigan-Curay stated that Journavx offers a non-opioid solution for acute pain, mitigating risks associated with opioid use and enhancing treatment options.
Collection
[
|
...
]